Jason Fangusaro
Overview
Explore the profile of Jason Fangusaro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Power P, Straehla J, Fangusaro J, Bandopadhayay P, Manoharan N
Neoplasia
. 2024 Dec;
59:101098.
PMID: 39637686
The last quarter century has heralded dramatic changes in the field of pediatric neuro-oncology, with the era defined by profound developments in the understanding of the biological underpinnings of childhood...
2.
Lim-Fat M, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J, et al.
Neuro Oncol
. 2024 Oct;
27(1):13-32.
PMID: 39441704
Adolescents and young adults (AYAs; ages 15-39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor...
3.
OHare P, Cooney T, de Blank P, Gutmann D, Kieran M, Milde T, et al.
Neuro Oncol
. 2024 May;
26(8):1357-1366.
PMID: 38743009
Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of...
4.
Fangusaro J, Avery R, Fisher M, Packer R, Walsh K, Schouten-van Meeteren A, et al.
Clin Cancer Res
. 2024 Feb;
30(11):2303-2308.
PMID: 38358393
In October 2022, the FDA Oncology Center of Excellence hosted an educational symposium entitled, "Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma (pLGG) Clinical Trials." The symposium brought...
5.
Mueller S, Fangusaro J, Thomas A, Jacques T, Bandopadhayay P, de Blank P, et al.
Neuro Oncol
. 2023 Dec;
26(3):407-416.
PMID: 38146999
Within the last few decades, we have witnessed tremendous advancements in the study of pediatric low-grade gliomas (pLGG), leading to a much-improved understanding of their molecular underpinnings. Consequently, we have...
6.
Fangusaro J, Jones D, Packer R, Gutmann D, Milde T, Witt O, et al.
Neuro Oncol
. 2023 Nov;
26(1):25-37.
PMID: 37944912
The most common childhood central nervous system (CNS) tumor is pediatric low-grade glioma (pLGG), representing 30%-40% of all CNS tumors in children. Although there is high associated morbidity, tumor-related mortality...
7.
Milde T, Fangusaro J, Fisher M, Hawkins C, Rodriguez F, Tabori U, et al.
Neuro Oncol
. 2023 Sep;
25(11):1920-1931.
PMID: 37738646
Pediatric low-grade gliomas (pLGGs) are the most common brain tumor in young children. While they are typically associated with good overall survival, children with these central nervous system tumors often...
8.
Leary S, Onar-Thomas A, Fangusaro J, Gottardo N, Cohen K, Smith A, et al.
Pediatr Blood Cancer
. 2023 Aug;
70 Suppl 6():e30600.
PMID: 37534382
Tumors of the central nervous system (CNS) are a leading cause of morbidity and mortality in the pediatric population. Molecular characterization in the last decade has redefined CNS tumor diagnoses...
9.
Monje M, Cooney T, Glod J, Huang J, Peer C, Faury D, et al.
Neuro Oncol
. 2023 Aug;
25(12):2262-2272.
PMID: 37526549
Background: Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood cancer with median survival of less than 1 year. Panobinostat is an oral multihistone deacetylase inhibitor with preclinical activity in...
10.
Pillay-Smiley N, Leach J, Lane A, Hummel T, Fangusaro J, de Blank P
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046770
Background: Understanding the effect of selumetinib on FASI may help elucidate the biology, proliferative potential, and role in neurocognitive changes for these NF1-associated lesions. Methods: Patients with NF1-associated LGG and...